Urology
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Durable

      *Lucrin Depot achieved durable suppression of testosterone below castrate levels (<50 ng/dL) for all doses in >93% of patients by Week 4 which was maintained for the duration of the study period1

      Flexible

      † 1-, 3-, 4- and 6-month dosing options1

      support

      ±Continued investment in physician education programs2

      au-lucrin-line
      Lucrin logo
      Lucrin logo
      Lucrin
      banner

      Active ingredient prescribing (AIP)

      CONSIDERATIONS WHEN PRESCRIBING LUCRIN

      • New Australian medicine regulations mean that from 1 February 2021, some prescriptions must include the active ingredient11
      • Lucrin Depot PDS has been included in the Government produced ‘List of Medicines for Brand Consideration’12
      • This list includes medicines prescribers should consider prescribing by brand as well as active ingredient, if clinically necessary for the treatment of their patient12
      • Handwritten scripts are not impacted by AIP11

      You can still choose LUCRIN.

      au-lucrin-logo-depot-pds1
      au-lucrin-logo-depot-pds2
      au-lucrin-logo-depot-pds3

       

      • Clinical software systems will now have been updated to alert prescribers when a prescribed medicine is on the Government ‘List of Medicines for Brand Consideration11
      •  Where you’ve made the clinical decision to treat with LUCRIN, simply complete these three steps to ensure it is dispensed 11,12
       

      Each software provider has developed their own solution to accommodate AIP. Refer to instructions provided by the software provider for specific workflow. Some practices/institutions may require you to request manual override for all options to be available.  Please note, handwritten scripts are exempt from AIP requirements as per Australian Government policy only. Individual institutions may have different requirements.

      au-onc-contact

      Contact an Account Manager

      Request a visit from an AbbVie Account Manager

      Discover more about our many products and services which can help you in your practice.

      Request now

      PBS Information

      Lucrin: Restricted benefit. Treatment of locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.

       

      Please review the full Product Information (PI) before prescribing, available below.

      Lucrin PI

      REFERENCES: 1. LUCRIN® Product Information. 2. AbbVie Data on File. CLA-AU-200014. 3. Spitz A, et al. Res Rep Urol 2016; 8:159-64. 4. Abbie Data on File. CLA-AU-200018. 5. Eligard Product Information. 6. Decapeptyl Package Leaflet. 7. Zoladex 3.6 mg implant Product Information. 8. Zoladex 10.8 mg implant Product Information. 9. Diphereline Product Information.10. Meani D et al. Ther Adv Urol 2018;10 (2 ):51–63  11. National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019 (F2019L01312),  accessed August 2021. 12. Australian Commission for Safety and Quality in Healthcare. List of Medicines for Brand Consideration (LMBC), accessed February 2021

      AbbVie®, LUCRIN® and LUCRIN Depot® are registered trademarks of AbbVie Inc. 


      AU-LUCR-210097
      Last revised August 2021